Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.
Systemic, splanchnic, and renal hemodynamics, intravascular volume, and reflexive and endocrine changes were measured before and after a single dose of fenoldopam, a novel antihypertensive agent that acts through stimulation of specific dopamine receptors. A 13% reduction in mean arterial pressure was mediated by a fall in total peripheral resistance association with an increase in cardiac index, heart rate, stroke volume, left ventricular ejection rate, and circumferential fiber shortening. Renal blood flow increased, thereby reducing the renal vascular resistance by more than 40%. In contrast, splanchnic hemodynamics failed to change. Likewise, there were no changes in intravascular volume, plasma renin activity, or norepinephrine, serum aldosterone, or prolactin levels.
D000284:Administration, Oral; D000328:Adult; D001552:Benzazepines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D018818:Fenoldopam; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007668:Kidney / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D011954:Receptors, Dopamine / Q000502:physiology*; D014655:Vascular Resistance / Q000187:drug effects
D001552:Benzazepines; D011954:Receptors, Dopamine; D018818:Fenoldopam; D009638:Norepinephrine